Is BXN a Buy at these levels or Bye see u later! - 1 Oct announcement below

Business has cash in bank..

has the USA pharmaceutical restrictions hurt the aspirations here?

BXN trying to put the holders at ease .. i guess .. BXN still bearish Tuesday 7th Oct

I checked Tamin's positive Takeaway here: Valuation 8cps and a possible Fy26 15cps.

Beyond Cannabis: Exploring Psychedelics

Perhaps most intriguingly, Bioxyne is positioning itself at the forefront of the emerging psychedelics market. They’ve already signed their first commercial contract for MDMA capsules used in PTSD treatment, seeing significant potential in this nascent therapeutic space.

Challenges and Opportunities

The medical cannabis sector remains volatile, with historical investor skepticism due to previous market failures. Bioxyne must continue to differentiate itself by emphasising its unique regulatory advantages, manufacturing expertise, and clear strategic vision. Apart from regulatory risks, the market is growing fast, with Germany legalising in 2024 and already running over $1B in sales and eclipsing Australia.

A Unique Investment Proposition

What sets Bioxyne apart is its approach to medical cannabis manufacturing. Like Foxconn in electronics, they’re building a business model centered on becoming the go-to manufacturing partner in a complex, regulated industry.

Their competitive advantages are multifaceted:

– Comprehensive regulatory licenses

– Advanced manufacturing infrastructure

– Highly skilled operational team

– Ability to manufacture multiple product types

– Efficient, scalable production processes

Looking Ahead

As the medical cannabis and psychedelics markets continue to mature, Bioxyne appears well-positioned to capitalise on growing demand. Their strategy of focusing on manufacturing excellence, rather than direct consumer sales, provides a more stable and potentially more profitable approach to this emerging industry unlike many peers who are yet to turn profitable.

With projected revenues approaching $100 million in 2-3 years, a lean cost structure, and expanding international footprint, Bioxyne represents an intriguing opportunity for investors seeking exposure to the specialty pharmaceutical and medical cannabis sector.

The TAMIM Takeaway

BXN ticks all the boxes we look for in a company:

⁃ Industry leader

⁃ Founder led and alignment with shareholders

⁃ High growth and profitable

⁃ Strong cashed up balance sheet and Free cashflow generation.

⁃ Track record of under promising and over delivering.

⁃ Significant room for growth in a large TAM

⁃ Under the radar with no institutional ownership or broker research – yet!

⁃ Large discount to our 8 cents valuation next year and potentially 15 cents if they can achieve $100 million of sales.

___________________________________________________________________________________________________

Disclaimer: Bioxyne (ASX: BXN) is held in TAMIM Portfolios as at date of article publication. Holdings can change substantially at any given time.

Can BXN scale -up the model here?

Outlook The Company is focussed on:

• Growing its manufacturing customer base in Australia, the UK and Europe;

• Substantially exceeding FY25 revenue performance in FY26;

• Gaining EU GMP certification in Czechia for distribution to European markets; and

• Launching its medicinal cannabis products in the UK and European markets with local partners. The Board intends on providing FY26 guidance at the release of the FY25 results next month. 

Revenue Group revenue (Figure 1) attributable to significant outperformance from BLS Australia and now enhanced by increased manufacturing capacity. The additional €3.2 million contract with Farmakem and Adrex will underpin growth into FY26. The Company is continuing to negotiate multiple additional contracts in both Australian and overseas markets, which will drive revenue expansion in FY26.

Outlook The Company is focussed on: • Growing its manufacturing customer base in Australia, the UK and Europe; • Substantially exceeding FY25 revenue performance in FY26; • Gaining EU GMP certification in Czechia for distribution to European markets; and • Launching its medicinal cannabis products in the UK and European markets with local partners. The Board intends on providing FY26 guidance at the release of the FY25 results next month. 

BXN seems to be delivering. Great for very early holders.

Return (inc div)   1yr: 900.00%   3yr: 43.28% pa   5yr: 30.92% pa

Thursday 24th July:

Last

5.0¢

Change

0.003(6.38%)

Mkt cap 

!

$101.7M

BXN has outperformed its growth forecasts over the last 12 months. In 2024 our goal was to become the leading medical cannabis manufacturer.

Micro cap;

'A microcap stock is a public company that has a market capitalization of roughly $50 million to $250 million. Companies with a market capitalization of less than $50 million are typically referred to as nanocap stocks'

Last

4.1¢

Change

0.001(2.50%)

Mkt cap !

$88.75M